Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies ...

Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...